BDKRB2 and neoplasm: Furthermore, since the affinity of labradimil for the bradykinin B2 receptor is lower than that for bradykinin[20,26], we would expect that labradimil would be less potent at increasing the leakiness of the BBTB, and therefore, increases in the transvascular flow rate across the BBTB mediated by labradimil would be overshadowed by the reduction in tumor blood flow.